Current Studies
If your screening results show you are in the early stages of T1D, you may be eligible to participate in a TrialNet prevention study.
TrialNet researchers are testing anti-thymocyte globulin (ATG) and teplizumab to compare their ability to delay the onset of type 1 diabetes (T1D) in people at high risk. Details
